SCHEMBL174430

SCHEMBL174430

Cn1ccc(C(F)(F)F)n1

nearest known ligand 0.41

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PRMT6 Q96LA8 1/20 0.41
KMT2A Q03164 1/20 0.40
KEAP1 Q14145 1/20 0.38
IDH1 O75874 3/20 0.36
LRRK2 Q5S007 2/20 0.36
KCNH2 Q12809 2/20 0.36
IDH2 P48735 1/20 0.36
SCN4A P35499 1/20 0.35
NPC1 O15118 3/20 0.35
MAPT P10636 2/20 0.35
RAB9A P51151 2/20 0.35
JMJD6 Q6NYC1 1/20 0.35
ALOX5 P09917 1/20 0.34
PTGS1 P23219 1/20 0.34
PTGS2 P35354 1/20 0.34
HTT P42858 1/20 0.33
PAX8 Q06710 1/20 0.33
NPSR1 Q6W5P4 1/20 0.33
LMNA P02545 1/20 0.33
MGLL Q99685 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL28247297 0.98 PRMT6 (0.40) PRMT6KMT2AKEAP1IDH1LRRK2
Bicarbonate SCHEMBL5617163 0.90 NPC1 (0.43) PRMT6KMT2ANPC1MAPTRAB9A
SCHEMBL2354268 0.82 KMT2A (0.38) KMT2AKEAP1LRRK2KCNH2SCN4A
SCHEMBL1086131 0.82 KMT2A (0.38) KMT2AKEAP1LRRK2KCNH2SCN4A
SCHEMBL27447582 0.81 CYP19A1 (0.41) PRMT6IDH1LRRK2KCNH2IDH2
SCHEMBL27656234 0.79 KEAP1 (0.42) PRMT6KMT2AKEAP1NPC1MAPT
SCHEMBL24050952 0.79 KMT2A (0.35) KMT2AKEAP1IDH1LRRK2KCNH2
SCHEMBL3120354 0.79 KMT2A (0.35) KMT2AKEAP1LRRK2KCNH2SCN4A
SCHEMBL2362310 0.79 KMT2A (0.35) KMT2AKEAP1LRRK2KCNH2SCN4A
SCHEMBL440932 0.78 KMT2A (0.41) KMT2AKEAP1SCN4ANPC1RAB9A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 562 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4127157-B1 MODIFIED DIPEPTIDE CLEAVASES, USES THEREOF AND RELATED KITS ENCODIA INC (US) 2026-02-11 EP claimed
US-12540131-B2 N-(heteroaryl) quinazolin-2-amine derivatives as LRRK2 inhibitors, pharmaceutical compositions, and uses thereof MERCK SHARP & DOHME LLC (US) 2026-02-03 US claimed
EP-4558481-A1 EMOPAMIL-BINDING PROTEIN INHIBITORS AND USES THEREOF Biogen MA Inc. (US) 2025-05-28 EP claimed
CN-118724897-A Beta-carboline compound containing pyrazole ring, synthesis method and antifouling application thereof 江苏科技大学 2024-10-01 CN claimed
WO-2024020156-A1 EMOPAMIL-BINDING PROTEIN INHIBITORS AND USES THEREOF BIOGEN MA INC. (US) 2024-01-25 WO claimed
CN-114957124-B 3- (trifluoromethyl) -pyrazole-4-carboxylic ester derivative and preparation method and application thereof 浙江工业大学 2023-11-07 CN claimed
CN-116924976-A Diaryl heterocyclic amine compound, preparation method, pharmaceutical composition and application thereof 中国医学科学院药物研究所 2023-10-24 CN claimed
EP-4217062-A1 CYCLOBUTYL AMIDE MONOACYLGLYCEROL LIPASE MODULATORS JANSSEN Pharmaceutica NV (BE) 2023-08-02 EP claimed
CN-116217467-A ERDRP-0519 intermediate and preparation method thereof 烟台皓元生物医药科技有限公司 2023-06-06 CN claimed
CN-115850178-A Preparation method of 1-methyl-3- (trifluoromethyl) -1H-pyrazole-5-alcohol 宁夏格瑞精细化工有限公司 2023-03-28 CN claimed
WO-2022063784-A1 CYCLOBUTYL AMIDE MONOACYLGLYCEROL LIPASE MODULATORS JANSSEN PHARMACEUTICA NV (BE) 2022-03-31 WO claimed
CN-113979944-A Synthesis method of high-selectivity 1-methyl-3- (trifluoromethyl) -1H-pyrazole-5-alcohol 杭州欧晨科技有限公司 2022-01-28 CN claimed
US-10772874-B2 Compounds and compositions for the inhibition of NAMPT VALO HEALTH, INC. 2020-09-15 US claimed
US-10456382-B2 Compounds and compositions for the inhibition of NAMPT FORMA TM, LLC (US) 2019-10-29 US claimed
US-20190105307-A1 NOVEL COMPOUNDS AND COMPOSITIONS FOR THE INHIBITION OF NAMPT Valo Health, LLC 2019-04-11 US claimed
US-20170368039-A1 NOVEL COMPOUNDS AND COMPOSITIONS FOR THE INHIBITION OF NAMPT FORMA TM, LLC (US) 2017-12-28 US claimed
US-20140294805-A1 NOVEL COMPOUNDS AND COMPOSITIONS FOR THE INHIBITION OF NAMPT VALO EARLY DISCOVERY, INC. 2014-10-02 US claimed
EP-2475644-B1 HSL INHIBITORS USEFUL IN THE TREATMENT OF DIABETES HOFFMANN LA ROCHE (CH) 2014-01-08 EP claimed
EP-2611804-A1 NOVEL COMPOUNDS AND COMPOSITIONS FOR THE INHIBITION OF NAMPT Forma TM, LLC. (US) 2013-07-10 EP claimed
WO-2012031197-A1 NOVEL COMPOUNDS AND COMPOSITIONS FOR THE INHIBITION OF NAMPT FORMA THERAPEUTICS, INC. (US) 2012-03-08 WO claimed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-12540131-B2 N-(heteroaryl) quinazolin-2-amine derivatives as LRRK2 inhibitors, pharmaceutical compositions, and uses thereof LRRK2, PARK7, SNCA PRMT6 1092/4885KMT2A 1633/4885KEAP1 306/4885
US-20190105307-A1 NOVEL COMPOUNDS AND COMPOSITIONS FOR THE INHIBITION OF NAMPT NAMPT, NNMT, NQO1 PRMT6 375/4885KMT2A 1615/4885KEAP1 361/4885
US-20170368039-A1 NOVEL COMPOUNDS AND COMPOSITIONS FOR THE INHIBITION OF NAMPT NAMPT, NNMT, NQO1 PRMT6 375/4885KMT2A 1615/4885KEAP1 361/4885
US-20140294805-A1 NOVEL COMPOUNDS AND COMPOSITIONS FOR THE INHIBITION OF NAMPT NAMPT, NNMT, NQO1 PRMT6 375/4885KMT2A 1615/4885KEAP1 361/4885
US-10772874-B2 Compounds and compositions for the inhibition of NAMPT NAMPT, NNMT, NQO1 PRMT6 373/4885KMT2A 908/4885KEAP1 258/4885
US-10456382-B2 Compounds and compositions for the inhibition of NAMPT NAMPT, NNMT, NQO1 PRMT6 373/4885KMT2A 908/4885KEAP1 258/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.